Fuzhou SASAC Party Secretary and Director Weng Guoping Leads Delegation to LBE Pharma for Research and Guidance, Praising Hard Core Technology in Advanced Drug Formulations

On the morning of May 13, 2026, Weng Guoping, Party Secretary and Director of the Fuzhou State-owned Assets Supervision and Administration Commission (SASAC), led a delegation to LBE Pharma for a research and guidance visit to gain in-depth understanding of the company's technological innovation and industrialization progress.

The delegation included Liu Yu, Party Secretary and Chairman of Fuzhou New Area Group, as well as relevant department heads from Fuzhou SASAC and Fuzhou New Area Group. Dr. Du Chuanjie, Chairman of LBE Pharma, warmly received the delegation together with the company’s core team and delivered a thematic presentation.

01 Showcasing Technological Strength: Three Core Platforms Build Competitive Advantage

In the company exhibition hall, Dr. Du systematically introduced LBE Pharma’s strategic focus on advanced drug formulation technologies, highlighting three core technology platforms: the “Integrated Hub for Innovation Drug-Device Combinations” the “Advanced Dual-Chamber Prefilled Syringe R&D and Production Platform,” and the “Complex Sustained-Release Formulation Development and Production Platform.”

Through physical demonstrations and comparative data analysis, he provided a comprehensive overview of the company’s innovation capabilities and competitive strengths in the field of advanced formulations—from R&D rationale and technological barriers to application scenarios.

He also expressed gratitude for Fuzhou’s favorable innovation and entrepreneurship ecosystem, as well as the comprehensive support provided by Fuzhou New Area Group in areas such as corporate establishment, space allocation, and resource coordination.

02 On-Site Inspection: Advanced Manufacturing Lines Receive High Recognition

Director Weng and his delegation visited the company’s advanced formulation manufacturing workshop. Dr. Tseng Weihong, Executive Vice President of LBE Pharma, introduced the production line layout, equipment operating status, process integration, and quality management system in detail. He also briefed the delegation on production capacity, order structure, and current operational challenges.

The delegation highly commended the company’s focus on the advanced formulation sector and its technology-driven development strategy. They noted that LBE Pharma’s strong and distinctive core competitiveness was clearly demonstrated both through the technical presentations and the on-site production line inspection.

03 Charting the Strategic Direction: Becoming a Driving Force for Industrial Upgrading

During the discussion session, Director Weng fully acknowledged the company’s development achievements. He emphasized that by anchoring its development in core technologies, LBE Pharma has achieved breakthroughs and partial import substitution in the advanced formulation sector.

He noted that the company’s development model—“building the enterprise on technology and driving breakthroughs through innovation”—is highly aligned with Fuzhou’s strategic direction of industrial transformation and upgrading. The company represents an important force in cultivating new quality productive forces and strengthening Fuzhou’s biopharmaceutical industrial cluster.

Dr. Du stated that the company will earnestly implement the guidance provided during the visit, continue to prioritize technological innovation as its core driver, accelerate the industrialization of its three core technology platforms, actively expand market presence, and strive to make greater contributions to upgrading Fuzhou’s biopharmaceutical industry and promoting high-quality economic development.